Nasdaq:DRMA
Dermata Therapeutics, Inc.
A pre-revenue biotech firm developing novel therapies for inflammatory skin diseases with a focus on atopic dermatitis.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock for its high-risk, high-reward potential in the lucrative dermatology market with a proprietary pipeline targeting major indications. The company has secured paid-in capital totaling $67.2M, providing a substantial buffer to advance candidates through critical clinical milestones before needing dilutive financing. If any drug candidate achieves positive trial data, the potential for value creation is significant given the current lack of commercial revenue.
Bear Case
The stock is heavily speculative due to zero revenue and a retained earnings deficit of $65.7M, indicating long-term financial distress if clinical trials fail. With total assets of only $3.5M and negative operating cash flow of $11.2M, the company lacks the liquidity to survive without continuous equity dilution or strategic partnerships. The widening annual losses suggest that current R&D investments are not yet offset by any commercial success, making the investment profile extremely volatile.
About Dermata Therapeutics, Inc.
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory skin diseases, primarily targeting atopic dermatitis and psoriasis. The company operates within the competitive skincare and dermatology market, leveraging its proprietary technology platforms to advance pipeline candidates through preclinical and clinical trials. With minimal current revenue, the firm relies heavily on strategic financing to fund research and development activities aimed at bringing innovative treatments to patients.
Analysis
Management Discussion
Dermata Therapeutics reported a net loss of $12.3M in 2024, an increase in burn rate compared to $9.6M in 2022 and $7.8M in 2023, signaling intensifying R&D costs or administrative overhead. Despite raising $6.9M through share issuances, the company's cash position has dwindled significantly from $7.4M to $3.2M over the last year, leaving limited runway for future operations. The widening deficit suggests that current financing may be insufficient to bridge the gap between R&D expenditure and available liquidity without immediate additional capital raises or successful asset sales.
Industry Overview
The dermatological therapeutics industry is characterized by high barriers to entry due to stringent regulatory requirements and the necessity for expensive clinical trials. Companies in this space often operate with long development cycles before achieving product launch and revenue generation. Success depends on demonstrating superior efficacy and safety profiles against existing treatments for conditions like psoriasis and eczema.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $9.7M | $8.0M | $12.5M |
| Operating Income | $-9.7M | $-8.0M | $-12.5M |
| R&D | $5.7M | $4.1M | $8.2M |
| G&A | $4.0M | $4.0M | $4.3M |
| Stock-Based Comp | $930.3K | $522.1K | $657.6K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | — | $247.2K | $225.8K |
| Pre-Tax Income | $-9.7M | $-8.0M | $-12.5M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-9.7M | $-8.0M | $-12.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-9.6M | $-7.8M | $-12.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-9.6M | $-7.8M | $-12.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $6.2M | — | — |
| Prepaid Expenses | $703.2K | $540.5K | $372.3K |
| Total Assets | $6.9M | $8.0M | $3.5M |
| Accounts Payable | $496.7K | $866.0K | $808.0K |
| Total Liabilities | $922.6K | $1.6M | $2.0M |
| Shareholders' Equity | $6.0M | $6.4M | $1.6M |
| Paid-In Capital | $51.6M | $59.7M | $67.2M |
| Retained Earnings | $-45.6M | $-53.4M | $-65.7M |
| Total L&E | $6.9M | $8.0M | $3.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-9.6M | $-7.8M | $-12.3M |
| Non-Cash Adjustments | $1.2M | $847.5K | $994.0K |
| Working Capital Changes | $-397.5K | $538.3K | $130.5K |
| Cash from Operations | $-8.8M | $-6.4M | $-11.2M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $4.3M | $7.6M | $6.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-4.6M | $1.2M | $-4.3M |
| Beginning Cash | $10.8M | $6.2M | $7.4M |
| Ending Cash | $6.2M | $7.4M | $3.2M |
Frequently Asked Questions
How does Dermata Therapeutics, Inc. make money?
The company's operations are centered on its drug discovery and development pipeline, specifically targeting the treatment of atopic dermatitis. Financially, all reported expenses relate to research and development ($8.2M) and general administrative functions ($4.3M), indicating a single-stage business model typical of clinical-stage biotechnology firms without significant commercial revenue streams yet.
What are the main risks for DRMA?
The company has no revenue and relies entirely on cash flow from financing ($6.9M) to sustain operations, creating high liquidity risk. Significant burn rates are evident with operating expenses of $12.5M against a net loss of $12.3M, threatening financial stability without successful clinical outcomes or new funding. There is substantial uncertainty regarding the success of its drug candidates in reaching the market and generating future sales. The company faces intense competition from established pharmaceutical players in the dermatology space.
What is DRMA's competitive advantage?
The company possesses proprietary technology platforms designed to target specific inflammatory pathways in skin diseases. Its focus on unmet needs within the atopic dermatitis market offers potential for high-value indications. The organization maintains a lean operational structure with low current liabilities relative to its asset base, preserving capital for R&D.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.